GLTO 7.03 Galecto, Inc.
| Range: | 6.5-23.5 | Vol Avg: | 35152 | Last Div: | 0 | Changes: | 0.39 |
| Beta: | 1.17 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Oct 29 2020 | Empoloyees: | 13 | ||
| CUSIP: | 36322Q107 | CIK: | 0001800315 | ISIN: | US36322Q1076 | Country: | US |
| CEO: | Dr. Hans T. Schambye M.D., Ph.D. | Website: | https://galecto.com | ||||
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Stock Details
GLTO 10
Galecto (GLTO) PT Raised to $10 at Oppenheimer
Jay Olson·Thu Oct 17 2024
Oppenheimer
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow